Beyang Secures $30 Million in Series A Financing
Technology firm Beyang has closed an oversubscribed Series A financing round totaling $30 million. The funds will accelerate the development of its AI-driven platform and advance clinical trials.
Chinese technology company Beyang announced it has closed a $30 million Series A financing round. The funding will be used to accelerate the iteration of its proprietary AI-driven ExCEED platform.
The capital infusion is also intended to advance the global clinical development of Beyang's pipeline. This includes a second-generation Menin inhibitor and a novel ophthalmic therapy.
Beyang's focus lies in leveraging artificial intelligence to streamline the discovery and development of new therapeutic options. The company did not disclose details regarding the investors or the specific impact on its global expansion plans.
The financing round signifies continued investment in AI-powered solutions within the pharmaceutical sector and positions Beyang to further its therapeutic pipeline.